A research team at the University of Pennsylvania (UPenn) has been working on preventing and treating genital herpes (HSV-2) for years and recently found success with an mRNA vaccine approach, even before the COVID-19 pandemic.
The goals of a HSV-2 vaccine are to keep the herpes virus dormant. Or if the virus escapes, prevent it from causing symptoms.
Professor Harvey M. Friedman demonstrated success in animal models in July 2020. This study found not only targeting entry molecules, but also targeting the HS-2 ability to evade the immune system.
Read More
